Academic Publication Resolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment
Correlated Market Trend: Delivery Driver
Bridging academia to market: The 60-day public search velocity mapping directly to the core technology of this paper. Dashed line represents 7-day moving average.
AI Semantic Synergy Context
Connecting this academic literature to real-world market discussions and products.
Resolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment
No description provided.
Multiscale architecture design of 3D printed biodegradable Zn-based porous scaffolds for immunomodulatory osteogenesis
AbstractReconciling the dilemma between rapid degradation and overdose toxicity is challenging in biodegradable materials when shifting from bulk to porous materials. Here, we achieve significant b...
Modulating nuclear stiffness and envelope barrier facilitates AAV nuclear entry and reduces immunogenicity
Low efficiency and immunotoxicity limit rAAVs clinical use. Here, the authors show that encapsulating rapamycin in PF127 micelles modulates cellular biomechanics, enhancing AAV-mediated gene transf...
Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets
AbstractThe immune response holds a pivotal role in cardiovascular disease development. As multifunctional cells of the innate immune system, macrophages play an essential role in initial inflammat...
Enhancing Drug Solubility, Bioavailability, and Targeted Therapeutic Applications through Magnetic Nanoparticles
Biological variability poses significant challenges in the development of effective therapeutics, particularly when it comes to drug solubility and bioavailability. Poor solubility across varying p...
Frequently Asked Questions (FAQ)
Curated market intelligence mapped to this research.
What is the core focus of the research titled 'Resolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment'?
This literature focuses on:
Which startups are commercializing the technology behind Resolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment?
Products like Nitro by Rocketlane are bringing this to market. Their focus is: AI agents for modern service delivery.
What other academic literature is closely related to 'Resolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment'?
Yes, highly correlated activity was mapped. An entry titled 'Resolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment' discusses this: No description provided.
Are there commercial applications of 'Resolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment' in market news publications?
Yes, highly correlated activity was mapped. An entry titled 'Modulating nuclear stiffness and envelope barrier facilitates AAV nuclear entry and reduces immunogenicity' discusses this: Low efficiency and immunotoxicity limit rAAVs clinical use. Here, the authors show that encapsulating rapamycin in PF127 micelles modulates cellula...
Cite this Market Intelligence Report
Reference our AI-mapped synergy between this research and the commercial market to instantly build authority.
Commercial Realization
Startups and Open Source tools heavily associated with the concepts explored in this paper.
-
Product HuntNitro by Rocketlane
Associated Media Narrative
- ZTO Express (Cayman) Q1 Earnings Call Highlights
- After A Year Of Waiting, Pokémon Has Finally Released One Of Its Best Anime Episodes In English
- METiS TechBio, the World's First Publicly Listed AI-Powered Drug Delivery Company, Debuts on the Hong Kong Stock Exchange, "The SpaceX of Pharmaceuticals" Ushers in a New Era of Biopharmaceuticals
SaaS Metrics